Metrics as of 10/17/2026, 08:53 AM (Berlin time), refresh in progress.
Nyxoah Stock
Nyxoah S.A.
Company data
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Country
- Belgium
- CEO
- Liam J. Kelly
- Employees
- 154
- Market cap
- $113 M
- IPO
- 28/04/2021
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.…
Nyxoah stock: price history
1D
-6.7%
1W
-18.4%
1M
-28.4%
6M
-66.0%
YTD
-75.9%
1Y
-81.2%
2Y
-88.3%
5Y
-95.6%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~11% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Nyxoah
Analyst assessment of Nyxoah
PRICE TARGET LOW
US$2.31
CONSENSUS
US$4.08
MEDIAN
US$3.50
PRICE TARGET HIGH
US$7.00
0
STRONG BUY
4
BUY
1
HOLD
0
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 17/08/2026
Nyxoah stock metrics
P/E
-0.46
P/B
0.68
EV/EBITDA
-1.18
RETURN ON EQUITY
-39.7%
NET MARGIN
-429.5%
DEBT/EQUITY
0.63
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
50.0%
FLOAT SHARES
50,881,022
AVG. DAILY VOLUME (30D)
198,658
Institutional holders
Comparable stocks
Frequently asked questions about Nyxoah stock
What does Nyxoah do?
Nyxoah S.A. is a company in the Healthcare sector, Medical - Specialties industry, headquartered in Belgium.
The CEO is Liam J. Kelly, the company employs around 154 people.
The IPO was on 28/04/2021; the stock trades on NASDAQ under the ticker NYXH.
What do analysts say about Nyxoah stock?
5 analysts rate the stock, the consensus is Buy (as of 17/08/2026).
The average price target is US$4.08, ranging from US$2.31 to US$7.00, with a median of US$3.50.
This is an external assessment, not a statement by Market Jury.
When does Nyxoah report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -11% stronger than usual.
Does Nyxoah pay a dividend?
No, Nyxoah currently does not pay a dividend.
Which stocks are comparable to Nyxoah?
Comparable stocks include STERIS, QuidelOrtho, Mesa Laboratories, 908 Devices, Trinity Biotech, Eli Lilly and Company, Johnson & Johnson and AbbVie.
How can I get Nyxoah stock analyzed?
Clicking "Analyze stock" lets five strategies assess Nyxoah against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.